Saturday, March 06, 2021 3:12:17 PM
Item thirteen says different:
13
attach to its answering brief is granted. We have determined to resolve the petition without
The Division’s unopposed motion for leave to file exhibits that it inadvertently failed to
scheduling an in-person hearing. See Rule of Practice 550(b), 17 C.F.R. § 201.550(b) (stating (footnote continued . . . ) trading suspension is no longer in effect, we have the authority to resolve Immunotech’s petition on the merits.14 Among other things, our decision to address the substance of Immunotech’s arguments promotes the development of the record in the event Immunotech seeks judicial review.
The SEC filed the suspension citing the claim is misleading.
At that time the SEC had no clue about this company or it’s manufacturing of the ImmunH.
Which would make sense if you are a start up and you make a claim in regard of having a medicine that can fight Ebola head on, that would draw a lot of suspicion.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM